---
figid: PMC4298491__10.1177_2040620714561581-fig3
figtitle: Signalling of the PI3K/AKT/mTOR pathway and relevant drugs that target each
  of the components of the pathway
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC4298491
filename: 10.1177_2040620714561581-fig3.jpg
figlink: /pmc/articles/PMC4298491/figure/fig3-2040620714561581/
number: F3
caption: 'Signalling of the PI3K/AKT/mTOR pathway and relevant drugs that target each
  of the components of the pathway. PI3K generates the lipid messenger PIP3, which
  mediates activation of several protein kinases, including AKT. AKT stimulates glycolysis
  and drives tumour cells to consume glucose and also promotes survival and cell-cycle
  progression. Protein synthesis, cell growth and proliferation, and metabolic functions
  downstream of AKT are regulated by the mTORC1 axis. Negative regulation of this
  pathway is conferred by PTEN, which cleave a phosphate group in PIP3. Abbreviations:
  GFR, growth factor receptor; EGFR, epidermal growth factor receptor; HER2, human
  epidermal growth factor receptor 2; BCR, B-cell receptor; mTORC, mammalian target
  of rapamycin complex; PIP2, phosphoinositide (4,5)-biphosphate; PIP3, phosphoinositide
  (3,4,5)-triphosphate; PTEN, phosphatase and tensin homologue; PI3K, phosphoinositide
  3′-kinase.'
papertitle: The biology behind PI3K inhibition in chronic lymphocytic leukaemia.
reftext: Valentín Ortiz-Maldonado, et al. Ther Adv Hematol. 2015 Feb;6(1):25-36.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.893059
figid_alias: PMC4298491__F3
figtype: Figure
redirect_from: /figures/PMC4298491__F3
ndex: 7e5e05b3-deb1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4298491__10.1177_2040620714561581-fig3.html
  '@type': Dataset
  description: 'Signalling of the PI3K/AKT/mTOR pathway and relevant drugs that target
    each of the components of the pathway. PI3K generates the lipid messenger PIP3,
    which mediates activation of several protein kinases, including AKT. AKT stimulates
    glycolysis and drives tumour cells to consume glucose and also promotes survival
    and cell-cycle progression. Protein synthesis, cell growth and proliferation,
    and metabolic functions downstream of AKT are regulated by the mTORC1 axis. Negative
    regulation of this pathway is conferred by PTEN, which cleave a phosphate group
    in PIP3. Abbreviations: GFR, growth factor receptor; EGFR, epidermal growth factor
    receptor; HER2, human epidermal growth factor receptor 2; BCR, B-cell receptor;
    mTORC, mammalian target of rapamycin complex; PIP2, phosphoinositide (4,5)-biphosphate;
    PIP3, phosphoinositide (3,4,5)-triphosphate; PTEN, phosphatase and tensin homologue;
    PI3K, phosphoinositide 3′-kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - RhoGAP1A
  - scb
  - gfr
  - nac
  - Akt
  - Pten
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Crtc
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - EGFR
  - ERBB2
  - BCR
  - RN7SL263P
  - RAPGEF5
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - ACKR2
  - CCR1
  - CCR10
  - CCR2
  - CCR3
  - CCR4
  - CCR5
  - CCR6
  - CCR7
  - CCR8
  - CCR9
  - ACKR4
  - CCRL2
  - CX3CR1
  - CXCR1
  - CXCR2
  - CXCR3
  - CXCR4
  - CXCR5
  - CXCR6
  - ACKR3
  - XCR1
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - RPTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AMELX
  - EPHB2
  - MAPK1
  - MAPK3
  - Perifosine
  - Temsirolimus
  - GSK690693
  - GDC-0941
  - AZD8055
  - Tyrosine
  - Sirolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
